Literature DB >> 22449073

Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.

Joseph J Buggy1, Laurence Elias.   

Abstract

BTK is a kinase that functions downstream of multiple receptors in various hematologic cells. This review focuses on BTK-dependent pathways that are likely to be involved in maintaining the malignant phenotype in B-cell lymphomas and leukemias. Survival of various B-cell malignancies requires BTK-dependent signals from the B-cell antigen receptor. Survival is also dependent on malignant cells homing to and interacting with lymphoid microenvironments, and these interactions are also BTK-dependent due its role in signaling downstream of chemokine and innate immune receptors. The potential for therapeutic targeting of BTK is currently being tested in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22449073     DOI: 10.3109/08830185.2012.664797

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  76 in total

Review 1.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

Review 2.  Targeting the B cell receptor pathway in non-Hodgkin lymphoma.

Authors:  Kelly Valla; Christopher R Flowers; Jean L Koff
Journal:  Expert Opin Investig Drugs       Date:  2018-06-07       Impact factor: 6.206

3.  Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

Authors:  Sarah E M Herman; Rashida Z Mustafa; Jennifer A Gyamfi; Stefania Pittaluga; Stella Chang; Betty Chang; Mohammed Farooqui; Adrian Wiestner
Journal:  Blood       Date:  2014-03-21       Impact factor: 22.113

Review 4.  Novel agents in mantle cell lymphoma.

Authors:  Anita Kumar
Journal:  Curr Oncol Rep       Date:  2015-08       Impact factor: 5.075

Review 5.  Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Blood       Date:  2012-08-08       Impact factor: 22.113

6.  Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma.

Authors:  Iván Fernández-Vega; Luis M Quirós; Jorge Santos-Juanes; María Pane-Foix; Teresa Marafioti
Journal:  Virchows Arch       Date:  2014-11-30       Impact factor: 4.064

Review 7.  Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?

Authors:  John C Allen; Fatima Talab; Joseph R Slupsky
Journal:  Int J Hematol Oncol       Date:  2016-05-26

8.  PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.

Authors:  Hiromichi Ebi; Carlotta Costa; Anthony C Faber; Madhuri Nishtala; Hiroshi Kotani; Dejan Juric; Patricia Della Pelle; Youngchul Song; Seiji Yano; Mari Mino-Kenudson; Cyril H Benes; Jeffrey A Engelman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-10       Impact factor: 11.205

9.  Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.

Authors:  Leila Kokabee; Xianhui Wang; Christopher J Sevinsky; Wei Lin Winnie Wang; Lindsay Cheu; Sridar V Chittur; Morteza Karimipoor; Martin Tenniswood; Douglas S Conklin
Journal:  Cancer Biol Ther       Date:  2015-09-18       Impact factor: 4.742

10.  Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.

Authors:  Rakesh Bam; Wen Ling; Sharmin Khan; Angela Pennisi; Sathisha Upparahalli Venkateshaiah; Xin Li; Frits van Rhee; Saad Usmani; Bart Barlogie; John Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Am J Hematol       Date:  2013-03-28       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.